title: Is medical treatment for angina the most cost-effective option?
abstract: A meta-analysis of the benefits of coronary artery bypass graft (CABG) surgery has been used as the basis of a model for comparing the costs and benefits of surgical and medical treatment of angina pectoris. In order to allow for the results of recent research, the economic model included the addition of aspirin and aspirin plus an HMG-CoA reductase inhibitor (statin) to medical management. The analysis indicates that in unselected patients the cost-effectiveness of CABG vs initial standard medical therapy over 5 years is towards the upper limit of what can be considered a cost-effective treatment both in terms of its effect on mortality (life-years gained) and morbidity (quality adjusted life-years). Addition of a statin to medical therapy reduced mortality and made coronary artery bypass graft surgery an expensive option in terms of improvement of quality of life. In patients with three-vessel disease or left ventricular dysfunction surgery appears fairly cost-effective in comparison with standard medical therapy but becomes relatively expensive when the benefits of aspirin or lipid-lowering therapy are added to medical treatment.
authors.affiliation: Medical Research Council Clinical Research Initiative in Heart Failure, University of Glasgow, U.K.
authors.forename: J G
authors.initials: JG
authors.lastname: Cleland
authors.forename: A
authors.initials: A
authors.lastname: Walker
mesh_terms: D000787:Angina Pectoris / Q000191:economics* / Q000401:mortality / Q000628:therapy; D015906:Angioplasty, Balloon, Coronary / Q000191:economics*; D001026:Coronary Artery Bypass / Q000191:economics*; D003327:Coronary Disease / Q000191:economics* / Q000401:mortality / Q000628:therapy; D003362:Cost-Benefit Analysis; D006801:Humans; D011788:Quality of Life; D015996:Survival Rate; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000191:economics* / Q000627:therapeutic use
chemical_list: D014665:Vasodilator Agents